Q-omics provides the consensus-scored RNY1P4 profile across patient tissues and cancer cell-line models. RNY1P4 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RNY1P4 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, RNY1P4 RNA expression shows 13,371 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, STAD, and THYM as cancer lineages where RNY1P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNY1P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNY1P4 survival associations across molecular data types. RNY1P4 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNY1P4 RNA expression–survival associations across cancer types. High RNY1P4 expression shows unfavorable associations in UVM, OV and ACC, but favorable associations in UCS, LIHC and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RNY1P4 RNA expression.
This table summarizes RNY1P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNY1P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNY1P4 shows lower tumor expression in THCA and higher tumor expression in STAD, LUAD, BRCA and HNSC. The STAD box plot shows higher RNY1P4 RNA expression in tumor versus normal tissue (log2 FC = +0.528, t-test p = .005).
This table shows molecular features associated with RNY1P4 in patient tissues and cancer cell lines. In patient samples, RNY1P4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
